1️⃣ FDA still has a commissioner problem Axios says Marty Makary appears to have been spared for now, after Reuters and others reported that the White House had signed off on a plan to fire him.
💡 Why it matters For sponsors, the issue is not gossip. It is review predictability at an agency already making abrupt calls on trials, vaccines and tobacco.
☕ Coffee talk How do you underwrite FDA timing when the commissioner is still the live variable?
2️⃣ Bizengri gets another fast FDA lane FDA approved Bizengri for NRG1 fusion-positive cholangiocarcinoma on May 8, calling it the seventh approval under the Commissioner’s National Priority Voucher pilot.
💡 Why it matters The signal is bigger than one ultra-rare label. FDA is showing how quickly it will move when a molecularly defined cancer has no clean standard option.
☕ Coffee talk How many tiny fusion baskets now look less tiny to FDA than to commercial teams?
3️⃣ Blackstone funds the EPI burden bet Blackstone Life Sciences is putting $250M into Anagram to fund ANG003, a non-porcine oral enzyme therapy for exocrine pancreatic insufficiency, including CF-related disease.
💡 Why it matters This is late private capital aimed at development, approval and launch, not platform optionality. The angle is product fit: fewer pills, different supply base, clearer payer story.
☕ Coffee talk If one tablet per meal is the pitch, who owns the porcine-enzyme shortage risk?